iOnctura SA, a clinical stage oncology company targeting core resistance and relapse mechanisms at the tumor-stroma-immune interface, announces it will present clinical and preclinical data on two pipeline assets, IOA-244 and IOA-289, at the European Society of Medical Oncology’s Immuno-Oncology Congress taking place on December 8–11, 2021 in Geneva, Switzerland and virtually.
November 23, 2021
· 3 min read